29. January 2010 17:18
The European Medicines Agency has pledged to improve access to medicines in its Road Map to 2015, a publication that coincides with the Agency’s 15th anniversary.
Stakeholders, including the pharmaceutical industry, and the public have been invited to comment on the Agency’s strategic vision, The European Medicines Agency Road Map to 2015: The Agency's contribution to Science, Medicines, Health.
Building on the achievements made by the previous Road Map initiative between 2005 and 2010, the focus of the new Road Map to 2015 is on continuous high-quality delivery of the Agency’s core business in an increasingly complex regulatory and scientific environment.
In addition, the document proposes three priority areas for future actions to strengthen the Agency’s role in protecting and promoting human and animal health in the EU:
- Addressing public health needs by: stimulating research and medicines development in areas of unmet medical need or for neglected and rare diseases; facilitating new and innovative approaches to the development of medicines; implementing effective preparedness plans to deal with public health threats.
- Facilitating access to medicines by: addressing the high attrition rate during the development process of medicines; improving the Agency’s model for the assessment of benefits and risks of medicines; improving the quality and scientific and regulatory consistency of the medicines review process.
- Optimising the safe use of medicines by: strengthening the evidence base on the benefits and risks of a medicine following its authorisation; applying novel pharmacovigilance methodologies and risk minimisation tools; taking patient experience into account for improved decision-making; becoming a reference point on information about medicines evaluated by the Agency.
The Agency will hold a number of workshops and face-to-face discussions as part of the public consultation process.